Acadia Pharmaceuticals Inc. is seeking a unique indication for its Nuplazid, for Parkinson's psychosis, but it remains up to FDA whether that separates it enough from other antipsychotic drugs to avoid a boxed warning.
Nuplazid (pimavanserin) is a part of a new class of non-dopaminergic antipsychotic drugs that are selective serotonin inverse agonists preferentially...